Hansa Biopharma Gestion

Gestion contrôle des critères 2/4

Le PDG Hansa Biopharma est Søren Tulstrup, nommé en Mar2018, a un mandat de 6.67 ans. La rémunération annuelle totale est SEK 27.51M, composée du salaire de 30.7% et des bonus 69.3%, y compris les actions et options de la société. détient directement 0.085% des actions de la société, d'une valeur de SEK 1.77M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 3.5 ans.

Informations clés

Søren Tulstrup

Directeur général

SEK 27.5m

Rémunération totale

Pourcentage du salaire du PDG	30.7%
Durée du mandat du directeur général	6.7yrs
Propriété du PDG	0.08%
Durée moyenne d'occupation des postes de direction	4.8yrs
Durée moyenne du mandat des membres du conseil d'administration	3.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Søren Tulstrup a-t-elle évolué par rapport aux bénéfices de Hansa Biopharma?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-SEK 655m
Jun 30 2024	n/a	n/a	-SEK 802m
Mar 31 2024	n/a	n/a	-SEK 845m
Dec 31 2023	SEK 28m	SEK 8m	-SEK 832m
Sep 30 2023	n/a	n/a	-SEK 856m
Jun 30 2023	n/a	n/a	-SEK 759m
Mar 31 2023	n/a	n/a	-SEK 678m
Dec 31 2022	SEK 26m	SEK 8m	-SEK 611m
Sep 30 2022	n/a	n/a	-SEK 626m
Jun 30 2022	n/a	n/a	-SEK 620m
Mar 31 2022	n/a	n/a	-SEK 583m
Dec 31 2021	SEK 26m	SEK 7m	-SEK 548m
Sep 30 2021	n/a	n/a	-SEK 491m
Jun 30 2021	n/a	n/a	-SEK 465m
Mar 31 2021	n/a	n/a	-SEK 431m
Dec 31 2020	SEK 21m	SEK 6m	-SEK 421m
Sep 30 2020	n/a	n/a	-SEK 426m
Jun 30 2020	n/a	n/a	-SEK 398m
Mar 31 2020	n/a	n/a	-SEK 381m
Dec 31 2019	SEK 11m	SEK 5m	-SEK 360m
Sep 30 2019	n/a	n/a	-SEK 330m
Jun 30 2019	n/a	n/a	-SEK 298m
Mar 31 2019	n/a	n/a	-SEK 274m
Dec 31 2018	SEK 8m	SEK 4m	-SEK 248m

Rémunération vs marché: La rémunération totale de Søren ($USD 2.49M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 739.28K ).

Rémunération et revenus: La rémunération de Søren a augmenté alors que l'entreprise n'est pas rentable.

PDG

Søren Tulstrup (59 yo)

6.7yrs

Titularisation

SEK 27,505,000

Compensation

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Søren Tulstrup	President & CEO	6.7yrs	SEK 27.51m	0.085% SEK 1.8m
C. Ballantyne	Chief Financial Officer	less than a year	pas de données	pas de données
Christian Kjellman	Senior VP & COO	4.8yrs	pas de données	pas de données
Hitto Kaufmann	Chief Scientific and R&D Officer	less than a year	pas de données	pas de données
Eva-Maria Joed	Vice President of Finance & Administration	5.5yrs	pas de données	pas de données
Klaus Sindahl	VP & Head of Investor Relations	no data	pas de données	pas de données
Anne Lanner	Senior VP & Chief Human Resources Officer	5.8yrs	pas de données	pas de données
Emanuel Björne	VP & Head of Business Development	no data	pas de données	pas de données
Lena Winstedt	Head of Science	no data	pas de données	pas de données
Vincenza Nigro	VP & Head of Medical Affairs	no data	pas de données	pas de données
Magnus Korsgren	VP & Head of Research and Development	3.6yrs	pas de données	pas de données

4.8yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0RC7 est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Florian Nicolas Reinaud	Director	less than a year	pas de données	pas de données
Anders Pedersen	Independent Director	6.5yrs	SEK 413.00k	0.0037% SEK 76.8k
Mats Blom	Independent Director	5.5yrs	SEK 493.00k	0.0015% SEK 30.6k
Peter Nicklin	Independent Chairman of the Board	2.4yrs	SEK 1.14m	0.036% SEK 751.7k
Eva Nilsagard	Independent Director	5.5yrs	SEK 591.00k	0.0044% SEK 92.0k
Hilary Malone	Independent Director	3.5yrs	SEK 725.00k	pas de données
Gunnar Tufveson	Chairman of European Medical Advisory Board in Transplantation	no data	pas de données	pas de données
Kathryn Wood	Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation	no data	pas de données	pas de données
Christophe Legendre	Member of European Medical Advisory Board in Transplantation	no data	pas de données	pas de données
Stanley Jordan	Chairman of US Medical Advisory Board in Transplantation	no data	pas de données	pas de données
Robert Montgomery	Member of US Medical Advisory Board in Transplantation	no data	pas de données	pas de données
Jonas Wikstrom	Director	less than a year	pas de données	pas de données

3.5yrs

Durée moyenne de l'emploi

59.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0RC7 sont considérés comme expérimentés (ancienneté moyenne 3.5 ans).

Hansa Biopharma Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Recent updates

Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

Third quarter 2024 earnings released: kr1.53 loss per share (vs kr4.78 loss in 3Q 2023)

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Second quarter 2024 earnings released: kr3.30 loss per share (vs kr4.79 loss in 2Q 2023)

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (Publ) Announces CFO Changes

No longer forecast to breakeven

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings released: kr4.78 loss per share (vs kr3.45 loss in 3Q 2022)

New minor risk - Profitability

New minor risk - Profitability

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings released: kr4.79 loss per share (vs kr3.82 loss in 2Q 2022)

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

New minor risk - Share price stability

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released: kr3.92 loss per share (vs kr3.11 loss in 1Q 2022)

Full year 2022 earnings released: kr13.57 loss per share (vs kr12.33 loss in FY 2021)

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Third quarter 2022 earnings released: kr3.45 loss per share (vs kr3.34 loss in 3Q 2021)

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

Senior VP recently bought kr346k worth of stock

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

Insider recently bought kr58k worth of stock

First quarter 2022 earnings released: kr3.11 loss per share (vs kr2.34 loss in 1Q 2021)

Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease

Full year 2021 earnings released: kr12.33 loss per share (vs kr9.98 loss in FY 2020)

Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its First-In-Class Treatment Idefirix® (imlifidase)

Hansa Biopharma AB Announces Positive Early Access Decision by French Haute Autorité De Santé to Use Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients